In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients

Clinical Immunology

Volumn 122, Issue 1, 2007, Pages 18-27

  Tobiásová, Zuzana ^a   Pospíšilová, Dagmar ^a   Miller, Ashley M ^c   Minárik, Ivo ^a,b   Sochorová, Klára ^a   Špíšek, Radek ^a   Rob, Lukáš ^b   Bartůňková, Jiřina ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dendritic cells; Immunotherapy; Ovarian cancer

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL MATURATION; CLINICAL ARTICLE; COCULTURE; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; OVARY CANCER; PRIORITY JOURNAL; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; APOPTOSIS; CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MIDDLE AGED; OVARIAN NEOPLASMS; PHAGOCYTOSIS;

EID: 33846005537     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.09.003     Document Type: Article

References (39)

1. Landis S.H., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 1999, CA. Cancer J. Clin. 49 (1999) 8-31
2. Ozols R.F., Bookman M.A., Connolly D.C., Daly M.B., Godwin A.K., Schilder R.J., Xu X., and Hamilton T.C. Focus on epithelial ovarian cancer. Cancer Cell 5 (2004) 19-24
3. U. Wagner, S. Kohler, S. Reinartz, P. Giffels, J. Huober, K. Renke, H. Schlebusch, H.J. Biersack, V. Mobus, R. Kreienberg, T. Bauknecht, D. Krebs, D. Wallwiener, Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001. Clin. Cancer Res. 7 (2001) 1154-1162.
4. Cannon M.J., Santin A.D., and O'Brien T.J. Immunological treatment of ovarian cancer. Curr. Opin. Obstet. Gynecol. 16 (2004) 87-92
5. Schuler G., Schuler-Thurner B., and Steinman R.M. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15 (2003) 138-147
6. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., and Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18 (2000) 767-811
7. Guermonprez P., Valladeau J., Zitvogel L., Thery C., and Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20 (2002) 621-667
8. Maier T., Tun-Kyi A., Tassis A., Jungius K.P., Burg G., and Dummer R. F.O. Nestle Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102 (2003) 2338-2344
9. Santin A.D., Hermonat P.L., Ravaggi A., Bellone S., Pecorelli S., Cannon M.J., and Parham G.P. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am. J. Obstet. Gynecol. 183 (2000) 601-609
10. + T cell immunity against B16 melanoma. J. Immunol. 171 (2003) 5940-5947
11. Schuler-Thurner B., Schultz E.S., Berger T.G., Weinlich G., Ebner S., Woerl P., Bender A., Feuerstein B., Fritsch P.O., Romani N., and Schuler G. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195 (2002) 1279-1288
12. Heiser A., Maurice M.A., Yancey D.R., Wu N.Z., Dahm P., Pruitt S.K., Boczkowski D., Nair S.K., Ballo M.S., Gilboa E., and Vieweg J. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J. Immunol. 166 (2001) 2953-2960
13. Schnurr M., Scholz C., Rothenfusser S., Galambos P., Dauer M., Robe J., Endres S., and Eigler A. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res. 62 (2002) 2347-2352
14. Scheffer S.R., Nave H., Korangy F., Schlote K., Pabst R., Jaffee E.M., Manns M.P., and Greten T.F. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int. J. Cancer 103 (2003) 205-211
15. + progenitor-derived dendritic cells. J. Exp. Med. 199 (2004) 1503-1511
16. Galea-Lauri J., Darling D., Mufti G., Harrison P., and Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol. Immunother. 51 (2002) 299-310
17. Marten A., Flieger D., Renoth S., Weineck S., Albers P., Compes M., Schottker B., Ziske C., Engelhart S., Hanfland P., Krizek L., Faber C., von Ruecker A., Muller S., Sauerbruch T., and Schmidt-Wolf I.G. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol. Immunother. 51 (2002) 637-644
18. Ragde H., Cavanagh W.A., and Tjoa B.A. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J. Urol. 172 (2004) 2532-2538
19. Brossart P., Wirths S., Stuhler G., Reichardt V.L., Kanz L., and Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96 (2000) 3102-3108
20. Iwashita Y., Tahara K., Goto S., Sasaki A., Kai S., Seike M., Chen C.L., Kawano K., and Kitano S. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol. Immunother. 52 (2003) 155-161
21. Zhao X., Wei Y.Q., and Peng Z.L. Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells. Immunol. Invest. 30 (2001) 33-45
22. Hirschowitz E.A., Foody T., Kryscio R., Dickson L., Sturgill J., and Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J. Clin. Oncol. 22 (2004) 2808-2815
23. Spisek R., Bretaudeau L., Barbieux I., Meflah K., and Gregoire M. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol. Immunother. 50 (2001) 417-427
24. Pospisilova D., Borovickova J., Rozkova D., Stary J., Seifertova D., Tobiasova Z., Spisek R., and Bartunkova J. Methods of dendritic cell preparation for acute lymphoblastic leukemia immunotherapy in children. Med. Oncol. 22 (2005) 79-88
25. Spisek R., Brazova J., Rozkova D., Zapletalova K., Sediva A., and Bartunkova J. Maturation of dendritic cells by bacterial immunomodulators. Vaccine 22 (2004) 2761-2768
26. Henry F., Boisteau O., Bretaudeau L., Lieubeau B., Meflah K., and Gregoire M. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res. 59 (1999) 3329-3332
27. Albert M.L., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89
28. Gallucci S., Lolkema M., and Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5 (1999) 1249-1255
29. + T cells for efficient tumor cell lysis. Cancer Res. 60 (2000) 4446-4452
30. Sauter B., Albert M.L., Francisco L., Larsson M., Somersan S., and Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191 (2000) 423-434
31. de Vries J., Lesterhuis W.J., Scharenborg N.M., Engelen L.P., Ruiter D.J., Gerritsen M.J., Croockewit S., Britten C.M., Torensma R., Adema G.J., Figdor C.G., and Punt C.J. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. 9 (2003) 5091-5100
32. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192 (2000) 1213-1222
33. Lutz M.B., and Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol. 23 (2002) 445-449
34. de Vries I.J., Krooshoop D.J., Scharenborg N.M., Lesterhuis W.J., Diepstra J.H., Van Muijen G.N., Strijk S.P., Ruers T.J., Boerman O.C., Oyen W.J., Adema G.J., Punt C.J., and Figdor C.G. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63 1 (2003) 12-17
35. A.P. Vicari, C. Caux, G. Trinchieri, Tumour escape from immune surveillance through dendritic cell inactivation. Semin. Cancer Biol. 12 (2002) 33_42.35.
36. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev., Immunol. 4 (2004) 941-952
37. Gabrilovich D.I., Corak J., Ciernik I.F., Kavanaugh D., and Carbone D.P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 3 (1997) 483-490
38. Kiertscher S.M., Luo J., Dubinett S.M., and Roth M.D. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J. Immunol. 164 (2000) 1269-1276
39. Sombroek C.C., Stam A.G., Masterson A.J., Lougheed S.M., Schakel M.J., Meijer C.J., Pinedo H.M., van den Eertwegh A.J., Scheper R.J., and de Gruijl T.D. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168 (2002) 4333-4343